A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Study Summary

The purpose of this study is to evaluate the clinical efficacy (GALAXI 1), clinical and endoscopic efficacy (GALAXI 2 and GALAXI 3) and safety of guselkumab in participants with Crohn's disease.

Conditions

Crohn's Disease

Interventions / Drugs

Guselkumab Dose 1 Guselkumab Dose 2 Guselkumab Dose 3 Guselkumab Dose 4 Guselkumab Dose 5 Guselkumab Ustekinumab Placebo

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment1409 participants

Primary Completion—

Lead SponsorJanssen Research & Development, LLC

Data Retrieved2026-04-11 02:55:31.550802+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.